Tavo Therapeutics Secures $17 Million Series A Financing to Advance Glaucoma and Retinal Disease Therapies

Tavo Biotherapeutics Secures $17 Million in Series A Funding to Advance Its Pipeline of Treatments for Glaucoma and Retinal Diseases, Accelerating Clinical and Preclinical Development

The company appointed Federico Grossi as Chief Medical Officer, Daniel Bradbury as Chairman, and Dominic Escher and Neil Gural joined the board of directors.

New funding will support the research and development of TAV-001 and TAV-002 to preserve vision and improve treatment outcomes for patients with glaucoma and retinal diseases.

Disclaimer: The market involves risks, and investment should be approached with caution. This article was generated by an AI large language model based on publicly available information and does not represent the views of Sina Finance. All information, data, and charts contained herein are for reference only and do not constitute any form of investment advice or basis for decision-making; please refer to actual announcements for authoritative information. For inquiries, please contact: biz@staff.sina.com.cn.

Responsible Editor: Xiaolang Express